The CD300LD Knockout CAL-27 Polyclonal Cells are a heterogeneous population of epithelial cells derived from the CAL-27 oral squamous cell carcinoma line, engineered via CRISPR/Cas9-mediated gene disruption to ablate CD300LD gene expression. This polyclonal knockout product retains the natural genetic diversity of the edited pool, providing a robust loss-of-function model without clonal selection artifacts. These cells are well-suited for investigating the functional roles of CD300LD in tumor cell biology and immune regulation.
CAL-27 is an adherent epithelial cell line originally isolated from a tongue squamous cell carcinoma in a 56-year-old male patient. It serves as a well-characterized model for oral squamous cell carcinoma research, exhibiting hallmark tumor properties including uncontrolled proliferation, migration, and invasive behavior. The genetic background of CAL-27 provides a relevant platform for studying oncogenic signaling pathways and tumor-immune interactions in head and neck cancers.
CD300LD encodes an inhibitory immune receptor containing immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in its cytoplasmic domain. Upon ligand engagement by molecules such as phosphatidylserine on apoptotic cells, CD300LD recruits and activates the tyrosine phosphatases SHP-1 and SHP-2. These phosphatases dephosphorylate key components of the PI3K-Akt signaling axis, leading to reduced Akt and mTOR activity and suppression of inflammatory cytokine production. Additionally, SHIP1 is recruited to further attenuate signaling. This ITIM-mediated inhibitory cascade establishes CD300LD as a critical modulator of immune responses, with potential implications in cancer immune evasion and inflammatory disease.
In the CAL-27 oral carcinoma context, loss of CD300LD function may disrupt negative regulatory circuits that tumor cells exploit to evade immune surveillance. By eliminating the inhibitory signals transduced through CD300LD, these knockout cells enable detailed investigation of how tumor-intrinsic immune modulators affect interactions with macrophages and other immune effectors. This model is particularly relevant for exploring the contribution of CD300LD to the immunosuppressive tumor microenvironment and its impact on PI3K-Akt-driven survival pathways in squamous cell carcinoma.
The CD300LD Knockout CAL-27 Polyclonal Cells are well-suited for a variety of functional assays, including western blotting and RT-qPCR to confirm CD300LD disruption, flow cytometry to assess surface receptor expression, cell proliferation and migration assays to evaluate tumor cell behavior, and co-culture experiments with macrophages to study immune evasion mechanisms. Researchers can use this model to screen for therapeutic targets aimed at blocking CD300LD-mediated inhibitory signaling, or to elucidate its role in the progression of oral squamous cell carcinoma. For additional information or technical support, please contact Ascent Research.
